# US 2010/0144040 A1 · Cells and methodology to generate non-segmented negative-strand rna viruses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0144040 A1
- Document ID: US20100144040A1
- Status: Published application
- Kind: A1
- Application number: 12/448,468
- Filed: 2007-12-21
- Published: 2010-06-10
- Earliest claimed: 2006-12-22
- Assignees: Institut Pasteur
- Inventors: Frédéric Tangy; Pierre Charneau; Yves Jacob
- Web page: https://patentgrep.com/patent/US20100144040A1

## CPC

- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C07K 14/005: from viruses
- C12N 15/86: Viral vectors
- C12N 2740/16021: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2740/16043: viral genome or elements thereof as genetic vector
- C12N 2740/16052: relating to complementing cells and packaging systems for producing virus or viral particles
- C12N 2760/18022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/18422: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2830/48: regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates to recombinant cells as well as to methods for the generation of non-segmented negative-sense single-stranded RNA viruses (NNV or mononegavirales) from cloned deoxyribonucleic acid (cDNA), especially from measles virus and in particular from attenuated strains such as those approved for vaccination, in particular from the attenuated Schwarz measles virus and various recombinant Schwarz measles-based viruses expressing heterologous sequences. Such rescued viruses can be used, after amplification, as vaccines for immunization against measles and/or against the heterologous peptides or proteins expressed.

## Claims

### Claim 1

A cell stably producing at least a RNA polymerase, a nucleoprotein (N) of a non-segmented negative-strand RNA virus and a phosphoprotein (P) of a non-segmented negative-strand RNA virus, or functional derivatives thereof.

### Claim 2 (depends on 1)

A cell according to claim 1, wherein the stable production does not result from a drug selection.

### Claim 3 (depends on 1)

A cell according to claim 1, comprising integrated in its genome: a. at least one copy of a nucleic acid encoding a RNA polymerase under the control of transcription regulatory element(s), b. at least one copy of a nucleic acid encoding a N protein of a non-segmented negative-strand RNA virus under the control of transcription regulatory element(s), and c. at least one copy of a nucleic acid encoding a P protein of a non-segmented negative-strand RNA virus under the control of transcription regulatory element(s).

### Claim 4 (depends on 1)

A cell according to any one of claim 1 comprising further at least one copy of a DNA flap integrated in its genome, said at least one DNA flap being functionally associated with said nucleic acid(s).

### Claim 5

A cell obtainable by recombination of its genome with: a. an expression vector comprising a DNA flap, and at least one copy of a nucleic acid encoding a RNA polymerase, b. an expression vector comprising a DNA flap, and at least one copy of a nucleic acid encoding a N protein of a non-segmented negative-strand RNA virus, and c. an expression vector comprising a DNA flap, and at least one copy of a nucleic acid encoding a P protein of a non-segmented negative-strand RNA virus.

### Claim 6

A cell obtainable by recombination of its genome with an expression vector comprising: a. at least one copy of a nucleic acid encoding a RNA polymerase. b. at least one copy of a nucleic acid encoding a N protein of a non-segmented negative-strand RNA virus. c. at least one copy of a nucleic acid encoding a P protein of a non-segmented negative-strand RNA virus, and d. a DNA flap.

### Claim 7 (depends on 1)

A cell according to claim 1 wherein the N and P proteins of a non-segmented negative-strand RNA virus are from the same virus.

### Claim 8 (depends on 7)

A cell according to claim 7, wherein the N and P proteins are from the same virus strain or different virus strains.

### Claim 9 (depends on 1)

A cell according to claim 1, wherein the N and P proteins of a non-segmented negative-strand RNA virus are from different segmented negative-strand RNA virus.

### Claim 10 (depends on 8)

A cell according to claim 8, wherein the N and P proteins of a non-segmented negative-strand RNA virus are from an attenuated MV virus, particularly Schwarz MV strain.

### Claim 11 (depends on 1)

A cell according to claim 1 wherein the RNA polymerase is the 17 phage RNA polymerase or its nuclear form (nlsT7).

### Claim 12 (depends on 1)

A cell according to claim 1, wherein the DNA flap is derived from a retrovirus.

### Claim 13 (depends on 12)

A cell according to claim 12, wherein the DNA flap is derived from a lentivirus, particularly a human lentivirus.

### Claim 14 (depends on 13)

A cell according to claim 13, wherein the DNA flap is derived from an HIV, CAEV, EIAV, VISNA, SIV or FIV virus.

### Claim 15 (depends on 14)

A cell according to claim 14 wherein the DNA flap is derived from HIV-1 or HIV-2.

### Claim 16 (depends on 5)

A cell according to claim 5, wherein said vector(s) is(are) HIV-derived transfer gene vector(s) comprising two LTR, one of the LTR being optionally deleted in the U3 part, and expression and transcription regulatory elements.

### Claim 17 (depends on 5)

A cell according to claim 5, wherein the vectors are: a. the plasmid HIV-1-TRIP[Delta]U3.CMV-T7 deposited with the CNCM on Dec. 14, 2006, under number I-3702 or the plasmid HIV-1-TRIP[Delta]U3.CMV-nlsT7 deposited with the CNCM on Dec. 14, 2006, under number I-3703, b. the plasmid HIV-1 -TRIP[Delta]U3.CMV-N deposited with the CNCM on Dec. 14, 2006, under number I-3700, and c. the plasmid HIV-1-TRIP[Delta]U3.CMV-P deposited with the CNCM on Dec. 14, 2006, under number 1-3701.

### Claim 18 (depends on 1)

A cell according to claim 1 which is an eukaryotic cell.

### Claim 19 (depends on 18)

A cell according to claim 18 which is a mammalian cell.

### Claim 20 (depends on 19)

A cell according to claim 19 which is a human cell.

### Claim 21 (depends on 1)

A cell according to claim 1 which can divide.

### Claim 22 (depends on 1)

A cell according to claim 1 which is HEK 293 (human embryonic kidney) cell.

### Claim 23 (depends on 22)

A cell according to claim 22 which is the 293-T7-NP cell line deposited with the CNCM on Jun. 14, 2006, under number I-3618.

### Claim 24 (depends on 22)

A cell according to claim 22 which is the 293-nlsT7-NP MV cell line deposited with the CNCM on Aug. 4, 2006, under number I-3662.

### Claim 25 (depends on 1)

A cell according to claim 1 which cannot divide.

### Claim 26 (depends on 3)

A cell according to claim 3 comprising integrated in its genome at least one copy of a nucleotide sequence encoding a RNA polymerase large protein (L) or functional derivatives thereof of a non-segmented negative-strand RNA virus, optionally under the control of transcription regulatory elements.

### Claim 27 (depends on 1)

A cell according to claim 1, further recombined by an expression vector comprising a nucleic acid encoding a RNA polymerase large protein (L) of a non-segmented negative-strand RNA virus, such as the pEMC-LSchw plasmid deposited with the CNCM on Dec. 18, 2007, under number 1-3881.

### Claim 28 (depends on 27)

A cell according to claim 27, wherein the expression vector is an expression vector comprising a DNA flap, and at least one copy of a nucleic acid encoding a L protein of a non-segmented negative-strand RNA virus.

### Claim 29 (depends on 26)

A cell according to claim 26, wherein the N, P and L proteins of a non-segmented negative-strand RNA virus are from the same virus.

### Claim 30 (depends on 29)

A cell according to claim 29, wherein the N, P and L proteins are from the same virus strain or different virus strains.

### Claim 31 (depends on 26)

A cell according to claim 26, wherein the N, P and L proteins of a non-segmented negative-strand RNA virus are from different non-segmented negative-strand RNA virus.

### Claim 32 (depends on 26)

A cell according to claim 26, wherein the L protein of a non-segmented negative-strand RNA virus is from a MV virus, particularly the Schwarz MV strain.

### Claim 33 (depends on 1)

A cell according to claim 1, further recombined with a cDNA clone encoding the full-length antigenome of a non-segmented negative-strand RNA virus.

### Claim 34 (depends on 33)

A cell according to claim 33, wherein the sequence of said non-segmented negative-strand cDNA clone is modified by insertion at permissive site(s) of heterologous nucleic acid(s).

### Claim 35 (depends on 1)

A cell culture which is composed of cells according claim 1.

### Claim 36 (depends on 35)

A cell culture according to claim 35 which is a primary culture.

### Claim 37 (depends on 35)

A cell culture according to claim 35 which is a cell line.

### Claim 38

An expression retroviral-derived vector, in particular a plasmid, comprising a DNA flap and at least one nucleic acid encoding a protein necessary for the rescue of a non-segmented negative-strand RNA virus.

### Claim 39 (depends on 38)

An expression retroviral-derived vector according to claim 38, wherein said nucleic acid encodes a protein that is selected from the group consisting of a RNA polymerase, a N protein of a non-segmented negative-strand RNA virus, a P protein of a non-segmented negative-strand RNA virus and a L protein of a non-segmented negative-strand RNA virus.

### Claim 40 (depends on 38)

An expression retroviral-derived vector according to claim 38 that is a FIV- or SIV-derived vector.

### Claim 41 (depends on 38)

An expression retroviral-derived vector according to claim 38 that is a human lentivirus such as a HIV-derived vector.

### Claim 42 (depends on 41)

An expression retroviral-derived vector according to claim 41 that is a HIV-1- or HIV-2-derived vector.

### Claim 43 (depends on 38)

An expression retroviral-derived vector according to claim 38 that comprises a DNA flap and a nucleic acid encoding a RNA polymerase, such as the plasmid HIV-1-TRIP[Delta]U3.CMV-T7 deposited with the CNCM on Dec. 14, 2006, under number I-3702.

### Claim 44 (depends on 38)

An expression retroviral-derived vector according to claim 38 that comprises a DNA flap and a nucleic acid encoding a nuclear form of a RNA polymerase, such as the plasmid HIV-1-TRIP[Delta]U3.CMV-nlsT7 deposited with the CNCM on Dec. 14, 2006, under number I-3703.

### Claim 45 (depends on 38)

An expression retroviral-derived vector according to claim 38 that comprises a DNA flap and a nucleic acid encoding a N protein of a non-segmented negative-strand RNA virus, such as the HIV-1-TRIP[Delta]U3.CMV-N deposited with the CNCM on Dec. 14, 2006, under number I-3700.

### Claim 46 (depends on 38)

An expression retroviral-derived vector according to claim 38 that comprises a DNA flap and a nucleic acid encoding a P protein of a non-segmented negative-strand RNA virus, such as the plasmid HIV-1-TRIP[Delta]U3.CMV-P deposited with the CNCM on Dec. 14, 2006, under number 1-3701.

### Claim 47 (depends on 38)

An expression retroviral-derived vector according to claim 38, that comprises a DNA flap and a nucleic acid encoding a L protein of a non-segmented negative-strand RNA virus.

### Claim 48 (depends on 38)

An expression retroviral-derived vector according to claim 38 that comprises a DNA flap and nucleic acid(s) encoding a RNA polymerase, a N protein of a non-segmented negative-strand RNA virus, a P protein of a non-segmented negative-strand RNA virus and optionally a L protein of a non-segmented negative-strand RNA virus.

### Claim 49

An expression vector comprising a nucleic acid encoding a L protein of a non-segmented negative-strand RNA virus, which is the plasmid pEMC-LSchw deposited with the CNCM on December 18, 2007, under number 1-3881.

### Claim 50 (depends on 38)

An expression vector according to claim 38, wherein said nucleic acid is under the control of transcription regulatory element(s), such as a promoter, for example the CMV promoter.

### Claim 51

Method to produce infectious, recombinant, non-segmented negative-strand RNA virus comprising or consisting of: a. recombining a cell or a culture of cells stably producing a RNA polymerase, a nucleoprotein (N) of a non-segmented negative-strand RNA virus and a polymerase cofactor phosphoprotein (P) of a non-segmented negative-strand RNA virus, with a non-segmented negative-strand cDNA clone and with a vector comprising a nucleic acid encoding a RNA polymerase large protein (L) of a non-segmented negative-strand RNA virus, b. transfer of said recombinant cell or culture of recombinant cells onto cells competent to sustain the replication and production of non-segmented negative-strand RNA virus, and c. recovering the infectious, recombinant, non-segmented negative-strand RNA virus from the co-culture of step b.

### Claim 52 (depends on 1)

Method to produce infectious, recombinant, non-segmented negative-strand RNA virus comprising or consisting of: a. recombining a cell or a culture of cells according to claim 1 with a non-segmented negative-strand cDNA clone and with an expression vector comprising a nucleic acid encoding a RNA polymerase large protein (L) of a non-segmented negative-strand RNA virus, b. transfer of said recombinant cell or culture of recombinant cells onto cells competent to sustain the replication and production of non-segmented negative-strand RNA virus, and c. recovering the infectious, recombinant, non-segmented negative-strand RNA virus from the co-culture of step b.

### Claim 53 (depends on 26)

Method to produce infectious, recombinant, non-segmented negative-strand RNA virus comprising or consisting of: a. recombining a cell or a culture of cells according to claim 26 with a non-segmented negative-strand cDNA clone and, b. transfer of said recombinant cell or culture of recombinant cells onto cells competent to sustain the replication and production of non- segmented negative-strand RNA virus, and c. recovering the infectious, recombinant, non-segmented negative-strand RNA virus from the co-culture of step b.

### Claim 54 (depends on 51)

Method according to claim 51, wherein said culture of cells is 293-T7-NP cell line deposited with the CNCM on Jun. 14, 2006, under number 1-3618 or 293-nlsT7-NP MV cell line deposited with the CNCM on Aug. 4, 2006, under number I-3662.

### Claim 55 (depends on 51)

Method according to claim 51, wherein said competent cells in step b. are Vera (African green monkey kidney) cells, CEF (chick embryo fibroblast) cells or MRCS cells.

### Claim 56

Method to produce infectious, recombinant, non-segmented negative-strand RNA virus comprising or consisting of: a. recombining a cell or a culture of cells stably producing a RNA polymerase, the nucleoprotein (N) of a non-segmented negative-strand RNA virus and the polymerase cofactor phosphoprotein (P) of a non-segmented negative-strand RNA virus, with a non-segmented negative-strand cDNA clone of a non-segmented negative strand RNA virus, and with a vector comprising a nucleic acid encoding a RNA polymerase large protein (L) of a non-segmented negative-strand RNA virus, and b. recovering the infectious, recombinant, non-segmented negative-strand RNA virus from said recombinant cell or culture of recombinant cells.

### Claim 57 (depends on 1)

Method to produce infectious, recombinant, non-segmented negative-strand RNA virus comprising or consisting of: a. recombining a cell or a culture of cells according to claim 1 with a non-segmented negative-strand cDNA clone of a non-segmented negative strand RNA virus and with an expression vector comprising a nucleic acid encoding a RNA polymerase large protein (L) of a non-segmented negative-strand RNA virus, and b. recovering the infectious, recombinant, non-segmented negative-strand RNA virus from said recombinant cell or culture of recombinant cells.

### Claim 58 (depends on 26)

Method to produce infectious, recombinant, non-segmented negative-strand RNA virus comprising or consisting of: a. recombining a cell or a culture of cells according to claim 26 with a non-segmented negative-strand cDNA clone of a non-segmented negative strand RNA virus, and b. recovering the infectious, recombinant, non-segmented negative-strand RNA virus from said recombinant cell or culture of recombinant cells.

### Claim 59 (depends on 56)

Method according to claim 56, wherein said cell or culture of cells is a eukaryotic cell culture, particularly a mammalian cell culture or a human cell culture.

### Claim 60 (depends on 59)

Method according to claim 59 wherein said cell culture is human fibroblasts, especially MRCS cell line (human lung fibroblasts).

### Claim 61 (depends on 51)

Method according to claim 51 wherein the nucleotide sequence of said non-segmented negative-strand cDNA clone of a non-segmented negative strand RNA virus is modified by insertion, at permissive sites, of at least one heterologous nucleic acid(s).

### Claim 62 (depends on 51)

Method according to claim 51 wherein said heterologous nucleic acid encodes epitopes or polyepitopes.

### Claim 63 (depends on 51)

Method according to claim 51, wherein said modified non-segmented negative-strand cDNA clone of a non-segmented negative strand RNA virus is from an attenuated MV virus, particularly the MV Schwarz strain.

### Claim 64 (depends on 21)

Method to produce recombinant cells according to claim 21 comprising or consisting in: a. recombining a cell with at least:
an expression vector comprising a DNA flap, and at least one copy of a nucleic acid encoding a RNA polymerase,
an expression vector comprising a DNA flap, and at least one copy of a nucleic acid encoding a N protein of a non-segmented negative-strand RNA virus, and
an expression vector comprising a DNA flap, and at least one copy of a nucleic acid encoding a P protein of a non-segmented negative-strand RNA virus, and b. selecting the cells that stably produce at least a RNA polymerase, a nucleoprotein (N) of a non-segmented negative-strand RNA virus and a phosphoprotein (P) of a non-segmented negative-strand RNA virus, or functional derivatives thereof.

### Claim 65 (depends on 21)

Method to produce recombinant cells according to claim 21 comprising or consisting in: a. recombining a cell with at least an expression vector comprising:—at least one copy of a nucleic acid encoding a RNA polymerase under the control of a promoter,
at least one copy of a nucleic acid encoding a N protein of a non-segmented negative-strand RNA virus under the control of a promoter,
at least one copy of a nucleic acid encoding a P protein of a non-segmented negative-strand RNA virus under the control of a promoter, and
a DNA flap, and b. selecting the cells that stably produce at least a RNA polymerase, a nucleoprotein (N) of a non-segmented negative-strand RNA virus and a phosphoprotein (P) of a non-segmented negative-strand RNA virus, or functional derivatives thereof.

### Claim 66 (depends on 26, 64, 65)

Method to produce recombinant cells according to claim 26 comprising or consisting in: a. providing recombinant cells by a method according to claim 64 or 65, b. further recombining the recombinant cells obtained in a. with an expression vector comprising a nucleic acid encoding a RNA polymerase large protein (L) or functional derivatives thereof of a non-segmented negative-strand RNA virus, and c. selecting the cells that stably produce at least a RNA polymerase, a nucleoprotein (N) of a non-segmented negative-strand RNA virus and a phosphoprotein (P) of a non-segmented negative-strand RNA virus, and that produce a large protein (L) of a non-segmented negative-strand RNA virus or functional derivatives thereof.

### Claim 67 (depends on 1)

Use of cells according to claim 1 as a helper cell line.

### Claim 68 (depends on 1)

Use of cells according to claim 1 to produce infectious, recombinant, non-segmented negative-strand RNA virus.
